United States — United States Securities and Exchange Commission & GT Biopharma
2 shared events · Importance 3 · Last updated Jul 30, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
United States — United States Securities and Exchange Commission: The SEC is relevant as the regulatory body overseeing securities laws; Immix filed a disclosure about the termination, and law firms may file complaints with the SEC.
GT Biopharma: GT Biopharma is the central company affected, having employed the fugitive executive. The company faces securities investigations and a significant stock price drop, potentially harming its reputation and financial standing.
Jul 20, 2026 · 20 articles
Business
United States — United States Securities and Exchange Commission: The SEC declared the shelf registration statement effective on July 10, 2026, enabling the offering.
GT Biopharma: GT Biopharma is the issuer of the offering, raising $125M to fund its oncology pipeline. The offering provides capital but dilutes existing shareholders.
Jul 14, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — United States Securities and Exchange Commission and GT Biopharma interact across events, view sentiment trends, and discover connected entities.
Open Dashboard